Trial Profile
Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibudilast (Primary) ; Temozolomide (Primary)
- Indications Astrocytoma; Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors MediciNova
- 19 Nov 2023 According to a MediciNova media release, data from this study presented at the 28th Annual Meeting of the Society for Neuro-Oncology
- 19 Nov 2023 Results published in the MediciNova Media Release
- 08 Sep 2023 Planned primary completion date changed from 30 Jun 2023 to 31 Dec 2023.